Skip to main content

Nutrition/Obesity

Dr. John Cush
@RheumNow
Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & https://t.co/ZbVwGTy0rG
Dr. John Cush
@RheumNow
The weight is off, the DMARDs are off - now what? Sometimes it’s only when we have effective solutions that we have to think about what to do next. And when that happens, remember why we do things in the first place. In an era when weight loss is happening on scale, now we need https://t.co/MTjU5YRS5q
Dr. John Cush
@RheumNow
Mediterranean Diet Lowers Incident Rheumatoid Arthritis Risk The American Journal of Clinical Nutrition has published the results of the SUN Project study, showing that long-term adherence to a Mediterranean diet (MedDiet) was associated with a substantially lower risk of https://t.co/9GhEwXuCEI
Dr. John Cush
@RheumNow
Bringing TOGETHER-PsA Into Clinical Practice The TOGETHER-PsA trial provides prospective evidence supporting an integrated approach to PsA and weight management, reinforcing the importance of addressing both inflammatory disease activity and metabolic health as part of https://t.co/WmF4mdxDWR
Dr. John Cush
@RheumNow
Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & https://t.co/qSXZkyYTmZ

Link Between Obesity and Psoriatic Arthritis

Jack Cush, MD

Obesity is an incidental comorbidity in psoriatic arthritis (PsA). It is a modifiable, mechanistically active driver of disease onset, severity, and treatment failure. A new comprehensive review in RMD Open (Madsen et al., 2026) synthesizes 49 studies suggesting that weight management belongs in

Dr. John Cush
@RheumNow
Lifestyle and Incretin Therapy Advice for Rheumatologists As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective by Kushner, et al. reframes lifestyle counseling as an adjunct to https://t.co/9dfmKLuJF7

The weight is off, the DMARDs are off - now what?

David Liew, FRACP

That promised land of substantive weight loss comes within it the illusion of better disease control and, for inflammatory arthritis patients, the possibility of reducing the burden of regular medicines - often driven by the patient, with or without telling you. It is a dream worth aspiring to

Dr. John Cush
@RheumNow
Obesity and Psoriatic Disease Obesity is a clinically important comorbidity in psoriasis (PsO) and psoriatic arthritis (PsA). Excess adiposity contributes to systemic inflammation and cardiometabolic risk and may adversely affect disease severity and response to some systemic https://t.co/WVIqfq8vEj

Bringing TOGETHER-PsA Into Clinical Practice

Eric Dein, MD

When Ms. RS came into my clinic for a new patient evaluation, she was suffering from highly active skin disease, joint swelling, pain and poor mobility. Her body mass index was 46, indicating class III obesity. A treatment plan focused solely on her inflammatory disease without addressing her

Dr. John Cush
@RheumNow
Rheum Survey: Beyond weight loss, How will GLP-1 drugs benefit rheumatic pts?
Dr. John Cush
@RheumNow
Lifestyle and Incretin Therapy Advice for Rheumatologists As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective reframes lifestyle counseling as an adjunct to pharmacotherapy - a https://t.co/ltPdGEgQ60

VA/DoD 2025 Obesity Guidelines

Jack Cush, MD

Annals of Internal Medicine has published the updated 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines on adult Overweight and Obesity management. Here is a review of the guidelines, including five key takeaways for rheumatologists.

×